Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: dirkdiggler who wrote (12080)	6/12/2013 11:37:18 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

The company was slow to 'lock data' after completion of the PII trial; then they had to confront the poor clinical response in stage IV and nodal stage III patients (now to be excluded from phase III trial design). It is likely that they tried several times to convince FDA that increased cumulative dosing should be allowed in the PIII trial, and during that time have been unsuccessful in finalizing their protocol. At this point, waiting a bit longer to incorporate info from the PI MOA studies is not unreasonable, as they may shed light on the company 'immune' MOA story that could play into final study design (new secondary end points or timing of sample collection to document responses). Dosing and MOA issues should have been worked out years ago. Back pedaling this late in the game takes time (3 years is not unreasonable, but strange that they did not press harder to get a trial started in Australia?). Unfortunately in that time the MM market has filled with a host of interesting new molecules and MOAs. It is likely that big pharma see's over-valued assets in PV-10 and PH-10 (based on product data available today, market advances by others, and current PVCT market cap) hence little interest in going at risk with research funding or a buy-out deal. A regional deal for HCC that included a commitment to fully fund development with up front and performance payments is still a possibility to keep PVCT afloat, but an MOU or thin commitment would be very troubling.

To: dirkdiggler who wrote (12080)	6/13/2013 11:05:03 AM
From: jm2i123	1 Recommendation Recommended By Jack Russell Read Replies (2) \| Respond to of 13111

1.you clearly have no knowledge or experience of how things work between phase2 and phase3. Yes things take forever. and that's the nature of the beast. Find me one investor, ONE, who says his/her biotech FDA-passed trials super fast, data released fast etc..etc..especially between phase2 and phase3 (and furthermore when an SPA is on the table, dozens of millions$ savings potential, etc..etc..) 2.If you're not happy to wait more, sell your shares. Investing in biotech is precisely that: Waiting. 3.they are not talking about selling the company to different bits they want to LICENSE the drug in some markets. Whats the problem with that? Wouldn't you do the same if you knew you could have a good shot at it, putting revenues on the spread sheet (better than debt) and thus hugely increasing the value of the business. Wouldn't you do that?